RAS mutation leading to acquired resistance to dabrafenib and trametinib therapy in a multiple myeloma patient harboring BRAF mutation

Multiple myeloma (MM) is still considered incurable and new therapeutic approaches are therefore needed. Deep‐sequencing analysis revealed the presence of BRAF mutations in up to 15% of patients. The clinical experience of BRAF‐targeted therapy in myeloma patients harboring BRAF mutation is still li...

Descripción completa

Detalles Bibliográficos
Autores principales: Le Calvez, Baptiste, Le Bris, Yannick, Herbreteau, Guillaume, Jamet, Bastien, Bossard, Céline, Tessoulin, Benoit, Gastinne, Thomas, Mahé, Béatrice, Dubruille, Viviane, Blin, Nicolas, Antier, Chloé, Theisen, Olivier, Kraeber‐Bodéré, Françoise, Le Gouill, Steven, Béné, Marie C., Moreau, Philippe, Touzeau, Cyrille
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9175793/
https://www.ncbi.nlm.nih.gov/pubmed/35847743
http://dx.doi.org/10.1002/jha2.8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9175793/
https://www.ncbi.nlm.nih.gov/pubmed/35847743
http://dx.doi.org/10.1002/jha2.8

Ejemplares similares